Unlike ROS1 kinase domain mutations that drive tyrosine kinase inhibitor (TKI) resistance in fusion-positive cancers[26], somatic ROS1-Mut in both the MSKCC [Figure 1A] and TCGA [Figure 1B] cohorts were distributed broadly across the protein (e.g., extracellular, transmembrane, cytoplasmic, and kinase domains). The gene discussed is ROS1; the disease is cancer.